Phase 1 Clinical Trial of AMG 340, a Prostate-Specific Membrane Antigen (Psma)-Targeted T-cell Engager with a Novel Low-Affinity CD3 Binding Domain Designed to Mitigate Toxicity for the Treatment of Metastatic Castration-Resistant Prostate Cancer (Mcrpc).
Journal of Clinical Oncology（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined